iScience, Volume 27

# Supplemental information

## Advances in biopharmaceutical products for hemophilia

Junzheng Wu, Xiaoling Liu, Huichuan Yang, Yanlin He, and Ding Yu

| 1  | Supplemental information   |
|----|--|
| 2  |  |
| 3  | Advances in biopharmaceutical products for hemophilia  |
| 4  |  |
| 5  | Junzheng Wu (武军政) <sup>1,4</sup> , Xiaoling Liu (刘小菱) <sup>1,4</sup> , Huichuan Yang (杨汇川) <sup>2</sup> , Yanlin He (何 |
| 6  | 彦林) <sup>3</sup> , Ding Yu (余鼎) <sup>1,3,5,*</sup>   |
| 7  |  |
| 8  | <sup>1</sup> Chengdu Rongsheng Pharmaceuticals Co., Ltd., Chengdu 610041, China  |
| 9  | <sup>2</sup> China National Biotec Group Company Limited, Beijing 100029, China  |
| 10 | <sup>3</sup> Beijing Tiantan Biological Products Co., Ltd., Beijing 100024, China                                      |
| 11 | <sup>4</sup> These authors contributed equally   |
| 12 | <sup>5</sup> Lead contact  |
| 13 |  |
| 14 | * Correspondence: <a href="mailto:yyuding@hotmail.com">yyuding@hotmail.com</a>   |
| 15 |  |




Figure S1. World map of coagulation factor VIII (FVIII) use per capita in 2022. FVIII per
capita serves as a general indicator of treatment levels owing to being the largest expenditure
in all care systems. Gray indicates no data reported for 2022. Data source: WFH Annual Global

20 Survey © Natural Earth.

21

## 22 Table S1. Clinical application characteristics of licensed biopharmaceuticals for hemophilia

| Category/product     |                            | Age group           | Half-life | Administration frequency and dosage |  |                               |
|----------------------|----------------------------|---------------------|-----------|-------------------------------------|--|-------------------------------|
| Approval information | Patient population         |                     |           | Prophylaxis                         | Episodic treatment   | Perioperative management      |
| Plasma-derived FVIII |                            |                     |           |                                     |  |                               |
|                      |                            |                     |           |                                     | Minor, moderate, and major                                       | Minor and major surgeries:    |
| A la havada          | PwHA without<br>inhibitors |                     |           | Not indicated                       | BE: twice daily, 15, 25, and                                     | twice daily. Initially, 40-50 |
| Alphanate            |                            | Adults              | 17.9 h.   |                                     | 40-50 IU/kg (30, 50, and   | IU/kg (80–100 IU/dL); the     |
| 1978 USA             |                            |                     |           |                                     | 80-100 IU/dL), respectively.                                     | next 7-10 days, 30-50 IU/kg   |
|                      |                            |                     |           |                                     | a  | (60–100 IU/dL). <sup>a</sup>  |
|                      |                            |                     |           |                                     | Early, and more extensive  |                               |
|                      | PwHA without               | Adults and children | 14.8 h    |                                     | BE: every 12–24 h, 20–40,  | Minor surgery: one single     |
| Hemofil M            |                            |                     |           |                                     | and 30-60 IU/dL,   | infusion, 60-80 IU/dL.        |
| 2001 USA             | inhibitors; PTPs and       |                     |           | Not indicated                       | respectively.  | Major surgery: every 8–24 h,  |
|                      | PUPs                       |                     |           |                                     | Life-threatening BE: every                                       | 80–100 IU/dL.                 |
|                      |                            |                     |           |                                     | 8–24 h, 60–100 IU/dL.  |                               |
|                      |                            |                     |           |                                     |  | Minor surgery: loading dose   |
| Humate-p             | PwHA without inhibitors    | Adults              | 12.2 h.   | Not indicated                       | Minor BE: once or twice daily, 15 IU/kg (30 IU/dL). <sup>a</sup> | 25 IU/kg (50 IU/dL);          |
| 1981 Germany         |                            |                     |           |                                     |  | followed by 15 IU/kg (30      |

|          |  |                        |                      |                       | Moderate BE: loading dose,        | IU/dL) every 8–12 h for 1–2       |
|----------|--|------------------------|----------------------|-----------------------|-----------------------------------|-----------------------------------|
|          |  |                        |                      |                       | 25 IU/kg (50 IU/dL);              | days. Then, once or twice         |
|          |  |                        |                      |                       | followed by 15 IU/kg (30          | daily for up to 7 days, 15        |
|          |  |                        |                      |                       | IU/dL) every 8–12 h for 1–2       | IU/kg (30 IU/dL). <sup>a</sup>    |
|          |  |                        |                      |                       | days. Then once or twice          | Major surgery: initially 40–      |
|          |  |                        |                      |                       | daily for up to 7 days, 15        | 50 IU/kg (80–100 IU/dL),          |
|          |  |                        |                      |                       | IU/kg (30 IU/dL). <sup>a</sup>    | followed by 20-25 IU/kg           |
|          |  |                        |                      |                       | Life-threatening BE: initially    | (40–50 IU/dL) every 8 h for       |
|          |  |                        |                      |                       | 40–50 IU/kg (80–100               | 7 days; then, once or twice       |
|          |  |                        |                      |                       | IU/dL), followed by 20–25         | daily for 7 days, 20–25           |
|          |  |                        |                      |                       | IU/kg (40–50 IU/dL) every 8       | IU/kg (40–50 IU/dL). <sup>a</sup> |
|          |  |                        |                      |                       | h for 7 days. Then, once or       |                                   |
|          |  |                        |                      |                       | twice daily for 7 days, 20-25     |                                   |
|          |  |                        |                      |                       | IU/kg (40–50 IU/dL). <sup>a</sup> |                                   |
|          |  |                        |                      |                       | Minor and moderate BE:            |                                   |
|          |  |                        |                      |                       | every 12–24 h, 30–40 IU/kg        |                                   |
| Wilate   | PwHA without                           |                        | Adults: OSA, 10.6 h. | Every 2–3 days, 20–40 | (60–80 IU/dL). <sup>a</sup>       |                                   |
| 2009 USA | Adults and adolescents OUSA inhibitors | Adults and adolescents | Adolescent (12–15    | IU/kg.                | Major BE: every 12–24 h,          | Not indicated                     |
|          |  |                        | y): OSA, 11.4 h.     |                       | 35–50 IU/kg (70–100               |                                   |
|          |  |                        |                      |                       | IU/dL). <sup>a</sup>              |                                   |

|  |   |  |                     |   | Life-threatening BE: every<br>8–24 h, 35–50 IU/kg (70–<br>100 IU/dL). <sup>a</sup>   |   |
|--|---|--|---------------------|---|--|---|
| Plasma-derived FIX<br>AlphaNine SD<br>1990 USA | PwHB without<br>inhibitors; PTPs and<br>PUPs. | Adults   | 21 h                | Not indicated                               | Minor and moderate BE:<br>twice daily, 20–30 and 25–<br>50 IU/kg (20–30 and 25–50<br>IU/dL), respectively. <sup>b</sup><br>Major BE: twice daily, 30–<br>50 IU/kg (30–50 IU/dL) at<br>least 3–5 days; then, 20<br>IU/kg (20 IU/dL). <sup>b</sup> | Minor and major surgeries:<br>twice daily, 50–100 IU/kg<br>(50–100 IU/dL). <sup>b</sup>     |
| Haemonine<br>2008 Germany                      | PwHB without<br>inhibitors                    | Adults, adolescents, and<br>children (≥ 6 y)             | Adults: OSA, 27.6 h | Interval of every 3–4 days,<br>20–40 IU/kg. | Early and more extensive<br>BE: every 24 h, 20–40 and<br>30–60 IU/dL, respectively.<br>Life-threatening BE: every<br>8–24 h, 60–100 IU/dL.   | Minor surgery: every 24 h,<br>30–60 IU/dL.<br>Major surgery: every 8–24 h,<br>80–100 IU/dL. |
| Nonafact<br>2001 EU                            | PwHB without inhibitors; PTPs                 | Adults, adolescents, and children ( $\geq 6 \text{ y}$ ) | 19 h                | Interval of every 3–4 days,<br>20–40 IU/kg. | Early and more extensive<br>BE: every 24 h, 20–40 and<br>30–60 IU/dL, respectively.  | Minor surgery: every 24 h,<br>30–60 IU/dL.  |

| Octanine F<br>2002 EU<br>Recombinant FVIII (SHL) | PwHB without<br>inhibitors; PTPs and<br>PUPs | Adults, adolescents, and children | Adults, adolescents:<br>29.1 h | Interval of every 3–4 days,<br>20–40 IU/kg | Life threatening: every 8–24<br>h, 60–100 IU/dL.<br>Early and more extensive<br>BE: every 24 h, 20–40 and<br>30–60 IU/dL, respectively.<br>Life threatening: every 8–24<br>h, 60–100 IU/dL. | Major surgery: every 8–24 h,<br>80–100 IU/dL.<br>Minor surgery: every 24 h,<br>30–60 IU/dL.<br>Major surgery: every 8–24 h,<br>80–100 IU/dL. |
|--|--|-----------------------------------|--------------------------------|--|---|--|
|  |  |                                   |                                |  | Minor BE: repeat dose if  |  |
|  |  |                                   | Adults and                     |  | there is evidence of further  |  |
|  | PwHA without                                 |                                   | adolescents (12-33             | Adults and adolescents: 3                  | bleeding, 20-40 IU/dL.  | Minor surgery: every 12–24   |
| Kogenate FS (FL)                                 | inhibitors; PTPs and                         | Adults, adolescents, and          | y): OSA, 13.7–14.6             | times weekly, 25 IU/kg.                    | Moderate BE: every 12–24  | h, 30–60 IU/dL.  |
| 1993 USA   | PUPs   | children                          | h.                             | Children: every other day, 25              | h, 30–60 IU/dL.   | Major surgery: every 6–12 h,   |
|  |  |                                   | Children (4.4–18.1             | IU/kg.                                     | Major BE: every 8–12 h.   | 100 IU/dL.   |
|  |  |                                   | y): OSA, 10.7 h.               |  | Initial: 80–100 IU/dL;  |  |
|  |  |                                   |                                |  | repeat: 40-50 IU/dL.  |  |
| Octocog alfa (FL)                                | PwHA without                                 |                                   | Adults: OSA, 12.9 h.           | Adults, adolescents, and OC:               | Minor and moderate BE:  | Minor surgery: every 24 h (adults, adolescents, and  |
| 2003 USA   | inhibitors; PTPs and<br>PUPs                 | All age groups                    | Adolescents: OSA,<br>12.1 h.   | interval of every 2–3 days,<br>20–40 IU/kg | every 12–24 h (adults,<br>adolescents, and OC), 8–12 h  | OC), or every 12–24 h (SC);<br>30–60 IU/dL.  |

|                                   |  |   | Children (2–12 y):<br>OSA, 9.6–11.8 h.<br>Infants (1 month to<br>< 2 y): OSA, 9.0 h. | SC: 3–4 times weekly, 20–50<br>IU/kg.  | (SC); 20–40, and 30–60<br>IU/dL, respectively.<br>Major BE: every 8–24 h<br>(adults, adolescents, and<br>OC), 6–12 h (SC), 60–100<br>IU/dL.         | Major surgery: every 8–24 h<br>(adults, adolescents, and<br>OC), every 6–24 h (SC); 80–<br>100 IU/dL. |
|-----------------------------------|--|---|--|--|---|---|
| Recombinate (FL)<br>1992 USA      | PwHA without<br>inhibitors; PTPs and<br>PUPs | Adults, adolescents, and children           | 14.6 h   | Not indicated  | Early and more extensive<br>BE: every 12–24 h, 20–40<br>and 30–60 IU/dL,<br>respectively.<br>Life threatening: every 8–24<br>h, 60–100 IU/dL.       | Minor surgery: a single<br>infusion, 60–80 IU/dL.<br>Major surgery: every 8–24 h,<br>80–100 IU/dL.    |
| Simoctocog alfa (BDD)<br>2015 USA | PwHA without inhibitors; PTPs                | Adults, adolescents, and<br>children (≥2 y) | Adults and<br>adolescents: OSA,<br>17.1 h.<br>Children: OSA,<br>11.9–13.1 h.         | Adults and adolescents:<br>every other day, 30–40<br>IU/kg.<br>Children: 3 times weekly or<br>every other day, 30–50<br>IU/kg. | Minor and moderate to major<br>BE: every 12–24 h, 20–40<br>and 30–60 IU/dL,<br>respectively.<br>Life-threatening BE: every<br>8–24 h, 60–100 IU/dL. | Minor surgery: every 24 h,<br>30–60 IU/dL.<br>Major surgery: every 8–24 h,<br>80–100 IU/dL.           |

| Turoctocog alfa (BDT)<br>2013 USA<br>Recombinant FVIII (EHL, inc       | PwHA without<br>inhibitors; PTPs and<br>PUPs | Adults, adolescents, and<br>children              | Adults and<br>adolescents: OSA,<br>10.8–12.8 h; TSA,<br>12.0–12.4 h.<br>Children: OSA, 7.7–<br>8.0 h; TSA, 9.4–10.0<br>h. | Adults and adolescents: 3<br>times weekly, 20–50 IU/kg;<br>or every other day, 20–40<br>IU/kg. Children: 3 times<br>weekly, 25–60 IU/kg; or<br>every other day, 25–50<br>IU/kg. | Minor, and moderate BE:<br>every 12–24 h, 20–40 and<br>30–60 IU/dL, respectively.<br>Major BE: every 8–24 h, 60–<br>100 IU/dL. | Minor surgery: every 24 h,<br>30–60 IU/dL.<br>Major surgery: every 8–24 h,<br>80–100 IU/dL.  |
|--|--|---|---|---|--|--|
| Damoctocog alfa pegol<br>(BDD, PEGylated)<br>2018 USA                  | PwHA without<br>inhibitors; PTPs             | Adults and adolescents                            | OSA, 17.4–21.4 h.<br>TSA, 17.9–18.6 h.  | Every 5 days, 45–60 IU/kg;<br>every 7 days, 60 IU/kg; or<br>twice weekly, 30–40 IU/kg   | Minor and moderate BE:<br>every 24–48 h, 20–40, and<br>30–60 IU/dL, respectively.<br>Major BE: every 8–24 h, 60–<br>100 IU/dL. | Minor surgery: every 24 h,<br>30–60 IU/dL.<br>Major surgery: every 12–24<br>h, 80–100 IU/dL. |
| Efanesoctocog alfa<br>(BDD, Fc-vWF-XTEN<br>fusion protein)<br>2023 USA | PwHA without inhibitors; PTPs                | Adults, adolescents, and<br>children <sup>c</sup> | Adults: OSA, 48.2 h.<br>Adolescents: OSA,<br>44.6 h.<br>Children (1–12 y):<br>OSA, 33.9–42.4 h.                           | Once weekly, 50 IU/kg   | Minor, moderate, and major<br>BE: every 2–3 days, 30–50<br>IU/kg (60–100 IU/dL). <sup>a</sup>                                  | Minor and major surgeries:<br>every 2–3 days, 30–50 IU/kg<br>(60–100 IU/dL). <sup>a</sup>    |

| Efmoroctocog alfa<br>(BDD, Fc fusion protein)<br>2014 USA | PwHA without<br>inhibitors; PTPs             | Adults, adolescents, and<br>children (≥1 y) | Adults: 19.7 h.<br>Adolescents: 16.4 h.<br>Children: 12.7–14.9<br>h.                            | Adults, adolescents and OC:<br>3–5 day intervals, 25–65<br>IU/kg.<br>SC: twice weekly, then 3–5<br>day intervals; 25–65 IU/kg. | Minor and moderate BE:<br>every 24–48 h (adults,<br>adolescents, and OC) or<br>every 12–24 h (SC); 40–60<br>IU/dL.<br>Major BE: every 12–24 h<br>(adults, adolescents, and<br>OC), or every 8–24 h (SC);<br>80–100 IU/dL. | Minor surgery: every 24 h<br>(adults, adolescents, and<br>OC), or every 12–24 h (SC);<br>50–80 IU/dL.<br>Major surgery: every 8–24 h<br>(adults, adolescents, and OC)<br>or every 6–24 h (SC); 80–<br>120 IU/dL. |
|---|--|---|---|--|---|--|
| Lonoctocog alfa<br>(BDT, Single-chain)<br>2016 USA        | PwHA without<br>inhibitors; PTPs and<br>PUPs | Adults, adolescents, and children           | Adults: TSA, 14.2 h.<br>Adolescents: TSA,<br>14.3 h.<br>Children: TSA,<br>10.2–10.4 h.          | 2–3 times weekly. Adults<br>and adolescents: 20–50<br>IU/kg; children: 30–50<br>IU/kg.   | Minor and moderate BE:<br>every 12–24 h; 20–40 and<br>30–60 IU/dL, respectively.<br>Major/life-threatening BE:<br>every 8–24 h, 60–100 IU/dL.   | Minor surgery: every 24 h,<br>30–60 IU/dL.<br>Major surgery: every 8–24 h,<br>80–100 IU/dL.  |
| Rurioctocog alfa pegol<br>(FL, PEGylated)<br>2015 USA     | PwHA without<br>inhibitors; PTPs and<br>PUPs | Adults, adolescents, and<br>children (≥1 y) | Adults: OSA, 14.7 h.<br>Adolescents: OSA,<br>13.4 h.<br>Children (2–12 y):<br>OSA, 11.8–12.4 h. | Twice weekly. Adults and<br>adolescents: 40–50 IU/kg;<br>children: 55 IU/kg.   | Minor and moderate BE:<br>every 12–24 h, 20–40 and<br>30–60 IU/dL, respectively.<br>Major BE: every 8–24 h, 60–<br>100 IU/dL.   | Minor surgery: every 24 h,<br>60–100 IU/dL.<br>Major surgery: every 8–24 h<br>(adults and adolescents) or<br>every 6–24 h (children); 80–  |

9

120 IU/dL.

|   |                                   |                                   |                           |                            | Minor BE: one dose, 40                 |                                   |
|---|-----------------------------------|-----------------------------------|---------------------------|----------------------------|--|-----------------------------------|
|   |                                   |                                   |                           |                            | IU/kg (80 IU/dL) for adults            | Minor surgery: additional         |
|   |                                   |                                   |                           |                            | and adolescents) or 65 IU/kg           | dose(s) after 24 h, 50 IU/kg      |
|   |                                   |                                   |                           |                            | (130 IU/dL) for children. <sup>a</sup> | (100 IU/dL) for adults and        |
|   |                                   |                                   | Adults: OSA, 21.7 h.      |                            | Moderate BE: additional                | adolescents or 65 IU/kg (130      |
| T   |                                   |                                   |                           | Adults and adolescents:    | dose after 24 h, 40 IU/kg (80          | IU/dL) for children. <sup>a</sup> |
| Turoctocog alfa pegol (BDT, GlycoPEGylated) | PwHA without inhibitors; PTPs and | Adults, adolescents, and          | Adolescents: OSA, 17.4 h. | every 4 days, 50 IU/kg.    | IU/dL) for adults and                  | Major surgery: additional         |
| 2019 USA                                    | PUPs                              | children                          | Children (1–12 y):        | Children: twice weekly, 65 | adolescents or 65 IU/kg (130           | doses every 24 h for the first    |
| 2019 03A                                    | rors                              |                                   | OSA, 13.8–14.7 h.         | IU/kg.                     | IU/dL) for children. <sup>a</sup>      | week; and then, every 48 h,       |
|   |                                   |                                   | OSA, 15.0–14.7 II.        |                            | Major BE: additional dose(s)           | 50 IU/kg (100 IU/dL) for          |
|   |                                   |                                   |                           |                            | every 24 h, 50 IU/kg (100              | adults and adolescents or 65      |
|   |                                   |                                   |                           |                            | IU/dL) for adults and                  | IU/kg (130 IU/dL) for             |
|   |                                   |                                   |                           |                            | adolescents or 65 IU/kg (130           | children. <sup>a</sup>            |
|   |                                   |                                   |                           |                            | IU/dL) for children. <sup>a</sup>      |                                   |
| Recombinant FIX (SHL)                       |                                   |                                   |                           |                            |  |                                   |
|   |                                   |                                   | Adults and                |                            | Minor, moderate, and major             |                                   |
| Nonacog alfa                                | PwHB without                      | Adults adolescents and            | adolescents: 21.5-        |                            | BE: every 12–24 h; 20–30,              | Minor and major surgery:          |
| -   | inhibitors; PTPs and              | Adults, adolescents, and children | 23.9 h.                   | Once weekly, 100 IU/kg     | 25–50, and 50–100 IU/dL,               | every 12-24 h; 25-50, and         |
| 1997 USA                                    | PUPs                              |                                   | Children (2–12 y):        |                            | respectively.                          | 50–100 IU/dL, respectively.       |
|   |                                   |                                   | 16.3–16.7 h.              |                            | respectively.                          |                                   |
|   |                                   |                                   |                           |                            |  |                                   |

### Infants (<2 y): 15.6

#### h.

| Nonacog gamma<br>2013 USA                                   | PwHB without<br>inhibitors; PTPs and<br>PUPs      | Adults, adolescents, and children | Adults and<br>adolescents: 25.7 h.<br>Children: 23.2–27.7<br>h.                                 | Twice weekly. Adults and<br>adolescents: 40–60 IU/kg;<br>children: 60–80 IU/kg.   | Minor, moderate, and major<br>BE: every 12–24 h; 20–30,<br>25–50, and 50–100 IU/dL,<br>respectively.   | Minor surgery: every 24 h,<br>30–60 IU/dL.<br>Major surgery: every 8–24 h,<br>80–100 IU/dL.  |
|---|---|-----------------------------------|---|---|--|--|
| Trenonacog alfa<br>2015 USA<br><b>Recombinant FIX (EHL)</b> | PwHB without inhibitors; PTPs                     | Adults and adolescents            | 24 h.   | Twice weekly, 40–70 IU/kg   | Minor and moderate BE:<br>every 24 h; 30–60 and 40–60<br>IU/dL, respectively.<br>Major and life-threatening<br>BE: every 12–24 h, 60–100<br>IU/dL.                   | Minor surgery: every 24 h,<br>30–80 IU/dL.<br>Major surgery: every 8–24 h,<br>20–80 IU/dL.   |
|   | llfa PwHB without<br>inhibitors; PTPs and<br>PUPs | All age groups                    | Adults: OSA, 95.3 h.<br>Adolescents: OSA,<br>88.8 h.<br>Children (1–12 y):<br>OSA, 86.2–89.3 h. | Adults and adolescents: once<br>weekly, 35–50 IU/kg; 10 or<br>14 day intervals, up to 75<br>IU/kg.<br>Children: once weekly, 35–<br>50 IU/kg. | Minor and moderate BE:<br>single dose. 30–60 IU/dL.<br>Major BE: repeat every 24–<br>72 h for the first week; and<br>then, maintenance dose<br>weekly. 60–100 IU/dL. | Minor surgery: single dose,<br>50–80 IU/dL.<br>Major surgery: every 24–72<br>h for the first week; and then,<br>1–2 times per week. 60–100<br>IU/dL. |

| Eftrenonacog alfa (Fc<br>fusion protein)<br>2014 USA | PwHB without<br>inhibitors; PTPs and<br>PUPs | Adults, adolescents, and<br>children (≥1 y) | Adults: OSA, 86–97<br>h.<br>Adolescents: OSA,<br>80–94 h.<br>Children (2–10 y):<br>OSA, 68–72 h           | Adults and adolescents: once<br>weekly, 50 IU/kg; or once<br>every 10 days, 100 IU/kg.<br>Children: once weekly, 60<br>IU/kg. | Minor and moderate BE:<br>every 48 h, 30–60 IU/dL.<br>Major BE: every 24 h for the<br>first 3 days; then, every ≥48<br>h. 80–100 IU/dL. | Minor surgery: single dose.<br>50–80 IU/dL.<br>Major surgery: every 24 h<br>for the first 3 days; and then,<br>every ≥48 h, 60–100 IU/dL.   |
|--|--|---|---|---|---|---|
| Nonacog beta pegol<br>(GlycoPEGylated)<br>2017 USA   | PwHB without<br>inhibitors; PTPs and<br>PUPs | Adults, adolescents, and children           | Adults: OSA, 83.0 h.<br>Adolescents (13–17<br>y): OSA, 89.4 h.<br>Children (≤ 12 y):<br>OSA, 69.3–76.3 h. | Once weekly, 40 IU/kg<br>(approved only in the EU)  | Minor, moderate, and major<br>BE: single dose; 40, 40, and<br>80 IU/kg, respectively.   | Minor surgery: single dose,<br>40 IU/kg.<br>Major surgery: pre-operative,<br>single dose, 80 IU/kg. Post-<br>operative: 1–3 day intervals<br>within the first week; then,<br>once weekly, 40 IU/kg. |
| Antibody<br>Concizumab<br>2023 Canada                | PwHB with inhibitors                         | Adults and adolescents <sup>d</sup>         | Single dose: 39–195<br>h;<br>multiple doses: 38 h.  | Once daily; loading dose: 1<br>mg/kg; maintenance dose:<br>0.2 mg/kg for 4 weeks; then,<br>0.15–0.25 mg/kg.                   | Not applicable  | Not applicable  |

| Emicizumab                | PwHA with or               |                        |                | Once every 1 (1.5 mg/kg), 2      |                |                |
|---------------------------|----------------------------|------------------------|----------------|----------------------------------|----------------|----------------|
|                           |                            | All age groups         | 26.9 days      | (3.0 mg/kg), or 4 (6.0 mg/kg)    | Not applicable | Not applicable |
| 2017 USA                  | without inhibitors         |                        |                | weeks                            |                |                |
|                           |                            |                        |                | Loading dose: 300 mg;            |                |                |
|                           |                            |                        |                | Maintenance dose: one week       |                |                |
|                           |                            |                        |                | after the loading dose, 150      |                |                |
| Marstacimab               | PwHA or PwHB               |                        | 5 10 1         | mg every week on the same        | N              | Not applicable |
| 2024 USA                  | without inhibitors         | Adults and adolescents | 7–10 days      | day each week.                   | Not applicable |                |
|                           |                            |                        |                | Dose adjustment to 300 mg        |                |                |
|                           |                            |                        |                | weekly can be                    |                |                |
|                           |                            |                        |                | considered.                      |                |                |
| Gene therapy              |                            |                        |                |                                  |                |                |
| Fidanacogene elaparvovec  |                            |                        |                | For one-time, single-dose,       |                |                |
| (pdv-FIX)                 | PwHB without               | Adults                 | Not applicable | intravenous use only; 5 $\times$ | Not applicable | Not applicable |
| 2024 Canada, USA and EU   | inhibitors                 |                        |                | $10^{11}$ vg/kg.                 |                |                |
| Etranacogene dezaparvovec |                            |                        |                | For one-time, single-dose,       |                |                |
| (pdv-FIX)                 | PwHB without<br>inhibitors | Adults <sup>e</sup>    | Not applicable | intravenous use only; 2 $\times$ | Not applicable | Not applicable |
| 2022 USA                  |                            |                        |                | $10^{13}$ gc/kg.                 |                |                |

| Valoctocogene            | PwHA without | For one-time, single-dose, |                |                                  |                |                |
|--------------------------|--------------|----------------------------|----------------|----------------------------------|----------------|----------------|
| roxaparvovec (BDD-FVIII) | inhibitors   | Adults <sup>f</sup>        | Not applicable | intravenous use only; 6 $\times$ | Not applicable | Not applicable |
| 2022 EU                  | minotors     |                            |                | 10 <sup>13</sup> vg/kg.          |                |                |

The information listed in this table was obtained from the product package inserts. Small children (SC), 0 to  $\leq 6$  y; older children (OC),  $\geq 6$  to  $\leq 12$  y; adolescents,  $\geq 12$  to  $\leq 18$  y;

24  $adults, \geq 18$  y. Abbreviations: OSA, one-stage clotting [activated partial thromboplastin time (APTT)] assay; TSA, two-stage (chromogenic) assay; BE, bleeding episode; PwHA,

- 25 patients with hemophilia A; PwHB, patients with hemophilia B; PTP, previously treated patients; PUP, previously untreated patients; SHL, standard half-life; EHL, extended half-
- 26 life; FL, full-length; BDD, B-domain deleted; BDT, B-domain truncated. EU, European Union; USA, United States of America; pdv-FIX, FIX-Padua variant; vg, vector genomes;
- 27 gc, genome copies.
- <sup>a</sup> One IU per kg body weight will increase the FVIII level by 2% of normal or 2 IU/dL.
- <sup>b</sup> One IU per kg body weight will increase the FIX level by 1% of normal or 1 IU/dL.
- 30 °Clinical trials of efanesoctocog alfa did not include sufficient numbers of participants aged  $\geq 65$  y to determine whether they responded differently from the younger participants.
- 31 However, clinical experience with other FVIII products has not revealed differences between older and younger patients.
- 32 <sup>d</sup> Clinical studies did not include sufficient numbers of patients aged  $\geq 65$  y to determine the overall benefit-risk profile of concizumab in these patients.

- 33 <sup>e</sup> Six geriatric participants with hemophilia B, aged 68–75 y at the time of enrollment, were included in the study. No meaningful differences in the safety and efficacy profile
- 34 were observed in these participants compared to participants aged 18–65 y, and no dose adjustment was made.
- 35 <sup>f</sup> A single patient aged  $\geq$  65 y was treated with valoctocogene roxaparvovec.